Aclaris Therapeutics, Inc.
ATI-045
Atopic Dermatitis
Countdown
56days
Phase 2 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 2 trial results for ATI-045 in Atopic Dermatitis are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07011706: Phase 2 trial, sponsor Aclaris Therapeutics, Inc., drug ATI-045. Primary completion date 2026-08 (estimated).”